Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma

Table 4 Survival times and progression times between cTACE and DEB-TACE treatments for patients with tumor number > 5 or sum of the diameter of the largest five HCC tumors was > 7 cm

Variables	cTACE	DEB-TACE	p-value
Variables	(n = 78)	(n = 33)	p-value
Survival status			0.610
Died within ≤5 years follow-up	62 (79.5)	26 (78.8)
Died after more than 5 years follow-up	3 (3.8)	0 (0)
Survived until last follow-up	13 (16.7)	7 (21.2)
Progression status			0.360
Progression	75 (96.2)	30 (90.9)
Loss of follow-up/censored	3 (3.8)	3 (9.1)
Survival time, months	31 (26.7, 35.3)	27 (22.3, 31.7)	0.789
Progression time, months	9 (6.7, 11.3)	12 (8.0, 16.0)	0.492

Survival and progression status are summarized as n (%) by treatment; Survival time- and progression time-related data are summarized as median (95%CI) by treatment
Differences between treatments were compared using Pearson Chi-square test / or Fisher’s exact test for survival and progression status and Log-rank test for survival time or progression time

ISSN: 1471-230X